Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxia telangiectasia and Rad3 related (ATR) is a serine/threonine protein kinase that plays a central role in the DNA damage response (DDR), particularly during DNA replication and in response to DNA damage. It is a key sensor of single-stranded DNA associated with stalled replication forks or intermediates generated during base excision repair (BER) and double-strand break repair. Upon activation, ATR initiates checkpoint signaling cascades that halt cell cycle progression for damage assessment/repair and phosphorylates downstream effectors like Chk1. Inhibitors targeting ATR are being developed as potential cancer therapeutics, especially for tumors with defects in other DDR components.
ATR inhibitors block the kinase activity of ATR, preventing the activation of downstream checkpoint signaling and DNA repair pathways, ultimately leading to cell death, especially in cells with other DDR defects.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxia telangiectasia and Rad3 related (ATR).